论文部分内容阅读
[目的]评价复方苦参注射液辅助双介入(肝动脉化疗栓塞加无水乙醇注射)治疗原发性肝癌的疗效及不良反应。[方法]对86例原发性肝癌患者进行连续3周期肝动脉化疗栓塞,化疗方案用FAM方案,并加用3周期无水乙醇肿瘤内注射,治疗组(46例)同时静脉点滴复方苦参注射液。对照组(40例)常规护肝治疗,并比较2组治疗前后肿瘤大小、Karnofsky评分、中医证候、T细胞亚群和不良反应情况。[结果]治疗组远期生存率高于对照组(P<0.05);Karnofsky评分、临床症状缓解率优于对照组(P<0.05),CD3+、CD4+、CD8+、CD4+/CD8+比值、NK细胞活性,2组比效差异有统计学意义(P<0.05),治疗组不良反应显著低于对照组。[结论]复方苦参注射液辅助双介入治疗原发性肝癌可提高远期生存率,调节免疫水平,改善生活质量,减轻不良反应。
[Objective] To evaluate the efficacy and side effects of compound Kushen injection in the treatment of primary hepatocellular carcinoma by double-intervention (hepatic arterial chemoembolization plus absolute ethanol injection). [Method] Totally 86 patients with primary hepatic carcinoma were treated with 3 cycles of hepatic arterial chemoembolization. FAM regimen was used in the chemotherapy regimen and 3 cycles of ethanol instillation was used. In the treatment group (46 cases), simultaneous intravenous injection of Compound Sophora flavescens Injection. The control group (40 cases) were given routine hepatoprotective therapy. The tumor size, Karnofsky score, TCM syndromes, T cell subsets and adverse reactions were compared between the two groups before and after treatment. [Results] The long-term survival rate of the treatment group was higher than that of the control group (P <0.05). The Karnofsky score and clinical symptom relief rate were better than those of the control group (P <0.05), and the ratio of CD3 +, CD4 +, CD8 +, CD4 + / CD8 + , The difference between the two groups was statistically significant (P <0.05), adverse reactions in the treatment group was significantly lower than the control group. [Conclusion] Fufang Kushen injection can improve the long-term survival rate, adjust the immune level, improve the quality of life and reduce the adverse reactions by treating the primary hepatocarcinoma with double interventional therapy.